Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

Antibody-based proteins have become an important class of biologic therapeutics, due in
large part to the stability, specificity, and adaptability of the antibody framework. Indeed …

Since the licensing of the first monoclonal antibody therapy in 1986, monoclonal antibodies
have become the largest class of biopharmaceuticals with over 80 antibodies currently …

Antibody discovery is bottlenecked by the individual expression and evaluation of antigen-
specific hits. Here, we address this bottleneck by developing a workflow combining cell-free …

From its start as a small‐scale in vitro system to study fundamental translation processes,
cell‐free protein synthesis quickly rose to become a potent platform for the high‐yield …

COVID-19, the disease induced by the recently emerged severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has imposed an unpredictable burden on the world. Drug …

Synthetic cells, artificial cell‐like particles, capable of autonomously synthesizing RNA and
proteins based on a DNA template, are emerging platforms for studying cellular functions …

Cell-free systems are a rapidly expanding platform technology with an important role in the
engineering of biological systems. The key advantages that drive their broad adoption are …

This review article concerns the production of recombinant antibody fragments for
applications mainly in the diagnostic sector. The so-called “point of care diagnostics” is very …

Recombinant antibody fragments are being used for the last few years as an important
therapeutic protein to cure various critical and life threatening human diseases. Several …